The PIRG-backed Inflation Reduction Act gave the Centers for Medicare and Medicaid Services (CMS) the ability to negotiate lower prices for prescription prices. Today, CMS announced the first ten medications that will be subject to price negotiation. About 8 million people will benefit from the lower prices obtained by the strong negotiating power of the federal government. Among the medications chosen, several are wrapped in patent thickets that mean a lower-cost generic version of the drug is still years away. Price negotiation will lower the cost of these drugs, even before a competing generic makes it to market. And that means significant savings for the patients who need them.